Randomized, double-blinded, placebo-controlled trial of ondansetron plus dexamethasone with or without metoclopramide as antiemetic prophylaxis in patients receiving high-dose cisplatin in medical practice

Supportive Care in Cancer

Volumn 20, Issue 4, 2012, Pages 849-855

  Ithimakin, Suthinee ^a   Runglodvatana, Kanakorn ^a   Nimmannit, Akarin ^a   Akewanlop, Charuwan ^a   Srimuninnimit, Vichien ^a   Keerativitayanan, Narong ^a   Soparattanapaisarn, Nopadol ^a   Laocharoenkeat, Apirom ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Anti emetic; Emetogenic chemotherapy; Metoclopramide

Indexed keywords

CISPLATIN; DEXAMETHASONE; METOCLOPRAMIDE; ONDANSETRON; PLACEBO;

ABDOMINAL PAIN; ADULT; ANOREXIA; ANTIEMETIC ACTIVITY; ARTICLE; CHEMOTHERAPY INDUCED EMESIS; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HICCUP; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 85027951896     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-011-1162-4     Document Type: Article

References (16)

1. Cohen L, de Moor CA, Eisenberg P, Ming EE, Hu H (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15:497-503
2. Blanchard EM, Hesketh PJ (2008) Nausea and vomiting. In: Devita VT, Lawrence TS, Rosenberg SA (eds) Cancer principles & practice of oncology, 8th edn. Lippincott Williams & Wilkins, Philadelphia, pp 2639-2646
3. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, Sumitsawan Y, Tharavichitkul E, Sukthomya V et al (2007) Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: randomized, non-inferiority, open trial. Eur J Cancer 43:1399-1406
4. National Comprehensive Cancer Network (2009) Antiemesis. National Comprehensive Cancer Network Guideline Version 4.2009
5. Hesketh PJ, Gandara DR (1991) Serotonin antagonists: a new class of antiemetic agents. J Natl Cancer Inst 83:613-620
6. Roila F, Warr D, Clarck-Snow RA, Tonato M, Gralla RJ, Einhorn LH et al (2005) Delayed emesis: moderately emetogenic chemotherapy. Support Care Cancer 13:104-108
7. Herrstedt J (2008) Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 5:32-43
8. Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic risk chemotherapy. Support Care Cancer 13:85-96
9. Hesketh PJ, Harvey WH, Harker WG, Beck TM, Ryan T, Bricker LJ et al (1994) A randomized, double-blinded comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin induced emesis. J Clin Oncol 12:596-600
10. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119
11. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie MG, Eldridge K, Hipple A et al (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting: results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97:3090-3098
12. Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim HK, Park K, Jordan K et al (2006) Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high dose cisplatin treatment. Ann Oncol 17:1000-1006
13. Herrstedt J, Sigsgaard T, Boesgaard M, Jensen TP, Dombernowsky P (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. N Engl J Med 328:1076-1080
14. Pearson JD, Cai B, Elmer W, Horgan K, Lindley C (2003) Assessing the impact of chemotherapy induced nausea and vomiting on patients' daily lives: a modified version of the Functional living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522-527
15. Picus J, Martin MG (2008) Gastrointestinal complications of chemotherapy. In: Perry MC (ed) The chemotherapy source book, 14th edn. Lippincott Williams & Wilkins, Philadelphia, pp 197-208
16. Roila F, Ballatori E, Angelis VD, Tonato M, Favero AD (1997) Ondansetron versus metoclopramide, both combined with dexamethasone, in prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124-130